Trial Profile
A comparative study of docetaxel and B.C.G interavesical with B.C.G alone for prophylaxis of post TUR bladder cancer recurrence.
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 14 Sep 2016
Price :
$35
*
At a glance
- Drugs Docetaxel (Primary) ; BCG
- Indications Bladder cancer
- Focus Adverse reactions; Therapeutic Use
- 21 Sep 2011 New trial record